NCT06926478View on ClinicalTrials.gov

Subconjunctival Humira for Boston Keratoprosthesis

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2028

Conditions
Penetrating KeratoplastyMultiple Graft FailureOcular Cicatricial PemphigoidStevens-Johnson Syndrome
Interventions
DRUG

Adalimumab Injection

10% (4.0mg/0.04ml) dissolved in sterile saline to be injected once during the time of the Boston Keratoprosthesis (Kpro) Surgery.

Trial Locations (1)

02114

Massachusetts Eye and Ear, Boston

All Listed Sponsors
lead

Massachusetts Eye and Ear Infirmary

OTHER